February 1, 2018
In this podcast and accompanying article, we interviewed Silke Bergheim-Pietza, Global Product Manager Depth Filtration, Pall. We discussed challenges faced in the cell harvesting step, in particular, selecting the best cell harvesting method based on the cell density and feed turbidity of the process and meeting the demand of increasing cell densities. Download the cell harvesting technology selection guide and use the guide to compare the latest single-use harvesting technologies.
January 30, 2018
In this podcast, we interviewed Jonathan Royce, Business Leader, Chromatography Resins, GE Healthcare Life Sciences, about the biggest challenges in Downstream biomanufacturing including overcoming bottlenecks, changing antibody structures and bioburden control. Jonathan shared how a purification platform can address some of these issues and discusses purification challenges that still need to be resolved.
December 12, 2017
In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis
December 6, 2017
In this podcast, we interviewed Jonathan Royce, Business Leader, Chromatography Resins, GE Healthcare Life Sciences, about the evolution of Protein A including the latest developments in Protein A chromatography resins. We also discussed what the future holds for this purification mainstay and how it can continue to address the changing needs of biopharma.
November 28, 2017
In this podcast, we interviewed Joakim Lundvist, Modality Manager, BioProcess™ Hardware, GE Healthcare about large-scale buffer management challenges. Buffer preparation is known to be one of the most resource-intensive activities in biomanufacturing as large volumes of buffers and process liquids are often required.
We examined the biggest challenges in buffer management and explored how technologies like inline conditioning can provide possible solutions.
November 8, 2017
In this podcast, we interviewed Alyssa Master, Ph.D., Senior Manager of Science and Applications, Nucleus Biologics about some of the challenges of working with FBS, why not all FBS is created equal and suggestions for FBS customers who are trying to navigate these issues.
We began the interview by discussing what FBS is and how it differs from other types of serum. Alyssa explained that FBS is a bi-product of the meat and dairy industry and it is great for in vitro cell growth because it contains a cocktail of growth factors. FBS is biochemically different from other sera like adult bovine serum or even newborn calf serum. Due to these biochemical differences, FBS has become the gold standard and as a result it is more expensive.
Alyssa continued that because of its ability to support cells in vitro it is widely used throughout academia, biotech, large pharma and bioproduction, particularly in cell therapy and vaccine biomanufacturing. I asked why so many use FBS and Alyssa said that it works well for most lines and is readily available. Because it is animal derived, it already contains cytokines and growth factors in the right combination to support cell growth.
View all show notes at:
October 24, 2017
In this podcast, we interviewed Dr. Adam Elhofy, Ph.D., Chief Scientific Officer, Bio-Ess, about the relationship between antibody titer and product quality attributes such as glycosylation. Dr. Elhofy shares his thoughts on both challenges and opportunities for optimizing both high titer and glycosylation profiles.
October 16, 2017
In this podcast, we interviewed Ken Clapp, a senior member of GE Healhcare Life Sciences' upstream product management team. We discussed the use of single-use bioreactors for fermentation, how single-use technology has evolved to meet the more rigorous demands of fermentation, and the benefits of single-use for this application.
October 14, 2017
In this podcast, we interviewed Ken Clapp, a senior member of GE Healthcare Life Sciences' upstream product management team. We explored in more detail the implementation of single-use systems for microbial fermentation including which processes make good candidates for single-use and considerations for transitioning from stainless steel.
June 22, 2017
In this podcast, we interviewed Jim McGorry, CEO and Saverio LaFrancesca, President and Chief Medical Officer about how Biostage is using cell therapy to improve the standard of care in adult and pediatric esophageal disease.
We began the interview talking with Dr. LaFrancesca about how Biostage is using their Cellframe technology to improve on the current standard of care for esophageal diseases. Dr. LaFrancesca began by explaining that esophageal disease patients are divided into two patient populations - adults and pediatric. For adults affected by esophageal disease or cancer the standard of care is to pull up their stomach to meet the remaining portion of esophagus after resection or to remove a section of the intestine and use it to replace the removed portion. These surgical procedures are very complicated and involve surgeries into multiple body cavities. The mortality and morbidity rate for these treatments is very high and have serious associated complications. In most pediatric cases the babies are born without an esophagus and in this case there is no standard of care. The surgeon will utilize the same techniques used in adult cases, but there are serious consequences for the infants including failure to thrive and issues with growth.
View all show notes at http://cellculturedish.com/2017/06/bioengineered-organ-implants-poised-to-change-treatment-paradigms-in-esophageal-cancer/